| Recruiting | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic D NCT07087912 | University of Sao Paulo General Hospital | Phase 4 |
| Withdrawn | A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) NCT07172022 | Hoffmann-La Roche | Phase 2 |
| Not Yet Recruiting | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases NCT07212322 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Not Yet Recruiting | Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies NCT07251179 | University Hospital, Strasbourg, France | — |
| Not Yet Recruiting | Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases NCT07301164 | Peking University Third Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome NCT07142239 | New Valley University | — |
| Recruiting | An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07236762 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases NCT07236801 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (I NCT07163338 | CHU de Reims | N/A |
| Recruiting | Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases NCT06828042 | Peking University Third Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Outcomes of Primary Versus Secondary Antiphospholipid Syndrome NCT06808607 | Assiut University | — |
| Recruiting | Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipi NCT06373926 | Centre Hospitalier Universitaire, Amiens | N/A |
| Recruiting | Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases NCT06614270 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008 | Peking University People's Hospital | Phase 2 |
| Recruiting | Negative Antiphospholipid Syndrome: a Multicentric Study NCT06373003 | Italian Society for Rheumatology | — |
| Not Yet Recruiting | The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases NCT06420154 | First Affiliated Hospital of Wenzhou Medical University | EARLY_Phase 1 |
| Recruiting | An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646 | China Immunotech (Beijing) Biotechnology Co., Ltd. | N/A |
| Recruiting | Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease NCT06373081 | Shanghai Changzheng Hospital | N/A |
| Recruiting | Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for Anti NCT05995600 | Seoul National University Hospital | Phase 4 |
| Recruiting | Anti-CD38 Antibody Treating APS With Thrombocytopenia NCT05983952 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Enrolling By Invitation | Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases NCT05859997 | Bioray Laboratories | N/A |
| Enrolling By Invitation | Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome NCT05583305 | Chinese University of Hong Kong | — |
| Unknown | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE NCT05644210 | Qilu Hospital of Shandong University | — |
| Recruiting | Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS NCT05646394 | McMaster University | — |
| Completed | Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant NCT05416190 | University Hospital, Clermont-Ferrand | N/A |
| Unknown | The BeLimumab Antiphospholipid Syndrome Trial (BLAST) NCT05020782 | University of Turin, Italy | Phase 2 / Phase 3 |
| Completed | Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infectio NCT05313048 | Cardioangiologisches Centrum Bethanien | — |
| Recruiting | Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytope NCT05199909 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Unknown | Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study) NCT05128760 | Central Hospital, Nancy, France | — |
| Unknown | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome NCT03684564 | University College, London | Phase 2 |
| Recruiting | Laboratory and Clinical Data in Antiphospholipid Patients NCT04308564 | Central Hospital, Nancy, France | — |
| Unknown | A Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Spontaneous Abortion With Antiphospholipid NCT04624269 | Shanghai First Maternity and Infant Hospital | Phase 4 |
| Recruiting | International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants NCT04262492 | Stéphane Zuily | — |
| Recruiting | Rheumatology Patient Registry and Biorepository NCT04402086 | Yale University | — |
| Completed | Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX) NCT03994302 | Groupe Hospitalier Pitie-Salpetriere | — |
| Recruiting | New Biological Tests in Patients With Antiphospholipid Antibodies NCT03890601 | Hospices Civils de Lyon | — |
| Completed | Prevalence of Antiphospholipid Antibodies in the Hemodialysis Patients Population Within the CHU Brugmann Hosp NCT03893357 | Brugmann University Hospital | — |
| Completed | Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter NCT03600636 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Completed | Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) NCT03682419 | LumiraDx UK Limited | N/A |
| Unknown | Measurement of Anti-dsDNA by Both CLIFT & ELISA NCT03303508 | Assiut University | N/A |
| Completed | Multi-organ Screening for Asymptomatic Ischaemia in Antiphospholipid Syndrome NCT03348306 | Central Hospital, Nancy, France | N/A |
| Unknown | Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome. NCT03384485 | Meir Medical Center | N/A |
| Completed | Evaluation of the Incidence of Cancer in the Follow-up of Women With 3 Consecutive Embryonic Demises Before 10 NCT03969498 | Centre Hospitalier Universitaire de Nīmes | — |
| Unknown | Antiphospholipid Antibodies and Early Severe Preeclampsia. NCT01538121 | Saint Thomas Hospital, Panama | — |
| Withdrawn | Pregnancy and Medically Assisted Conception in Rare Diseases NCT02450396 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Antiphospholipid Antibodies and Fetal Growth Restriction NCT01538134 | Saint Thomas Hospital, Panama | — |
| Completed | Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome NCT05195372 | Cardioangiologisches Centrum Bethanien | — |
| Completed | Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome NCT02295475 | Scott C. Woller, MD | Phase 4 |
| Completed | Timing of Initiation of LMWH Administration in Pregnant Women With APS NCT02326051 | Mohamed Sayed Abdelhafez | Phase 4 |
| Terminated | Rivaroxaban in Thrombotic Antiphospholipid Syndrome NCT02157272 | University of Padova | Phase 3 |
| Unknown | Use of Warfarin After the First Trimester in Pregnant Women With APS NCT02303171 | Mohamed Sayed Abdelhafez | Phase 4 |
| Terminated | Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome NCT01649479 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Completed | Rivaroxaban for Patients With Antiphospholipid Syndrome NCT02926170 | Hospital Universitari Vall d'Hebron Research Institute | Phase 3 |
| Unknown | The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syn NCT01818505 | National Taiwan University Hospital | — |
| Terminated | Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients NCT01784523 | Hospital for Special Surgery, New York | Phase 3 |
| Completed | Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholip NCT04153201 | National and Kapodistrian University of Athens | N/A |
| Completed | Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome NCT01660061 | Johann Wolfgang Goethe University Hospital | — |
| Completed | Pharmacogenetics of Warfarin in Puerto Ricans. NCT01318057 | University of Puerto Rico | — |
| Completed | Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic NCT01475149 | Hospital for Special Surgery, New York | — |
| Unknown | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases NCT01151644 | University of Sao Paulo | Phase 4 |
| Completed | Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With NCT00878137 | University of North Carolina, Chapel Hill | — |
| Completed | Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients NCT00674297 | Hospital for Special Surgery, New York | Phase 2 |
| Completed | A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome NCT00537290 | Hospital for Special Surgery, New York | Phase 2 |
| Completed | Drug Interaction Between Paracetamol and Warfarin NCT01104337 | Hopital Lariboisière | Phase 4 |
| Recruiting | Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationall NCT00616317 | University of California, Davis | — |
| Recruiting | Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome NCT00482794 | Duke University | — |
| Withdrawn | Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss NCT00180778 | Imperial College London | Phase 1 / Phase 2 |
| Withdrawn | Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome NCT00278616 | Richard Burt, MD | Phase 1 |
| Completed | Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corres NCT02833194 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections NCT02855047 | Centre Hospitalier Universitaire de Nīmes | — |
| Recruiting | Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) NCT00198068 | Hospital for Special Surgery, New York | — |
| Completed | Antiphospholipid Syndrome Collaborative Registry (APSCORE) NCT00076713 | University of North Carolina, Chapel Hill | — |
| Completed | Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies. NCT00180817 | Imperial College London | — |